Cargando…
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3
Proteasome inhibitors represent a novel class of drugs that have clinical efficacy against hematological and solid cancer types, including acute myeloid leukaemia, myelodysplastic syndrome an non-small cell lung cancer. It has been demonstrated that the anti-apoptotic protein B-cell lymphoma-2-assoc...
Autores principales: | Yuan, Ting, Zhang, Feng, Zhou, Xiangxiang, Li, Ying, Zhang, Ya, Xu, Yangyang, Wang, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403502/ https://www.ncbi.nlm.nih.gov/pubmed/30881494 http://dx.doi.org/10.3892/ol.2019.10029 |
Ejemplares similares
-
Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling
por: Yang, Juan, et al.
Publicado: (2020) -
PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma
por: Pfeifer, Matthias, et al.
Publicado: (2013) -
Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells
por: TIAN, FENG, et al.
Publicado: (2015) -
Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells
por: Tian, Feng, et al.
Publicado: (2023) -
PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma
por: Chen, Jianfeng, et al.
Publicado: (2020)